The Technology Strategy Board, together with the Department of Health, the Scottish Government Health Directorates, the Medical Research Council, Cancer Research UK and the National Institute for Health and Clinical Excellence (NICE) is to bring the government, researchers and business together in a major initiative that will place the UK at the centre of a revolution in the diagnosis and treatment of disease.
The new programme - called the Stratified Medicines Innovation Platform - will oversee an investment of over £50 million of government funding in innovative research and development in areas such as tumour profiling to improve cancer care and developing biomarkers for more effective drugs. The first competitions, worth up to £11 million, open in January 2011.
The Innovation Platform will initially focus on two specific areas:
- Tumour profiling in cancer, with an initial focus on breast, lung, colorectal, prostate, ovarian and skin cancers and associated technologies;
- Biomarker implementation to provide validated tests for predicting responses to marketed drugs, or drugs in development, in health conditions of clinical and commercial importance to the UK.
Companies and other organisations seeking further information about funding competitions managed by the Technology Strategy Board should visit the competitions page of the Technology Strategy Board website on www.innovateuk.org
You need to be a member of Life Sciences Scotland to add comments!
Join Life Sciences Scotland